Edition:
United Kingdom

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

11.80EUR
4:35pm BST
Change (% chg)

€0.21 (+1.81%)
Prev Close
€11.59
Open
€11.64
Day's High
€11.97
Day's Low
€11.61
Volume
100,715
Avg. Vol
124,142
52-wk High
€18.87
52-wk Low
€8.30

Latest Key Developments (Source: Significant Developments)

Nanobiotix Launches Capital Increase By Means Of Accelerated Bookbuild Offering
Monday, 8 Apr 2019 

April 8 (Reuters) - NANOBIOTIX SA ::JEFFERIES INTERNATIONAL LIMITED ("JEFFERIES") IS ACTING AS SOLE BOOKRUNNER FOR OFFERING.NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING.TO ISSUE UP TO 2,566,666 NEW ORDINARY SHARES OF A NOMINAL VALUE OF EUR 0.03 ("NEW SHARES").ADMISSION OF NEW SHARES TO TRADING ON EURONEXT PARIS ARE EXPECTED TO OCCUR ON OR ABOUT APRIL 11, 2019.OFFERING WILL COMMENCE IMMEDIATELY AND IS EXPECTED TO END BEFORE MARKETS OPEN ON REGULATED MARKET OF EURONEXT PARIS TOMORROW.  Full Article

Nanobiotix Announces Hencify Received European Market Approval
Thursday, 4 Apr 2019 

April 4 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL.THIS APPROVAL REPRESENTS SIGNIFICANT STEP FORWARD IN ESTABLISHING NBTXR3 AS A MAJOR ONCOLOGY TREATMENT.AFTER POSITIVE PHASE II/III DATA, THIS APPROVAL REPRESENTS SIGNIFICANT STEP FORWARD IN ESTABLISHING NBTXR3 AS A MAJOR ONCOLOGY TREATMENT.HENSIFY (NBTXR3) RECEIVED EUROPEAN MARKET APPROVAL (CE MARK) ENABLING COMMERCIALIZATION IN 27 EUROPEAN UNION COUNTRIES FOR TREATMENT OF LOCALLY ADVANCED SOFT TISSUE SARCOMA.POST-APPROVAL TRIALS ARE PLANNED ACROSS EUROPE AND DISCUSSIONS ON NEXT STEPS REGARDING POTENTIAL FURTHER DEVELOPMENT ARE ONGOING.  Full Article

Nanobiotix Q3 Revenue Down At 21,816 Euros
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUES EUR 21,816 VERSUS EUR 33,018 YEAR AGO.  Full Article

Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros
Friday, 30 Mar 2018 

March 30 (Reuters) - NANOBIOTIX SA ::TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016.CASH AVAILABLE AT DECEMBER 31, 2017 AMOUNTS TO EUR 47.2M..FY NET LOSS EUR ‍​26.1 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO.2018 SHOULD BE ANOTHER YEAR OF GROWTH.FY CORE OPERATING LOSS EUR 24.9 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO.EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA IN Q2 2018..  Full Article

Nanobiotix FY Revenue Down At ‍​0.3 Million Euros
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - NANOBIOTIX SA ::FY REVENUE EUR ‍​0.3 MILLION VERSUS EUR 1.6 MILLION YEAR AGO.TO PRESENT RESULTS OF SOFT TISSUE SARCOMA PHASE II/III TRIAL WITH NBTXR3 IN Q2 2018‍​.TO START IN Q2 2018 PHASE I/II CLINICAL TRIAL OF NBTXR3 ACTIVATED BY RADIOTHERAPY WITH ANTI-PD1 ANTIBODY IN CANCER PATIENTS‍​.  Full Article

Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS.COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR.WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S..HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND.  Full Article

Nanobiotix Q3 revenue down at 33.0‍​ million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO.  Full Article

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology
Monday, 13 Nov 2017 

Nov 13 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PRESENTED NEW CLINICAL AND PRE-CLINICAL DATA CONFIRMING NBTXR3'S SIGNIFICANT POTENTIAL ROLE IN IMMUNO-ONCOLOGY AT SITC ANNUAL MEETING.‍PATIENTS TREATED WITH NBTXR3 AND RADIOTHERAPY SHOW A MARKED INCREASE OF PD1 AND CD8 INFILTRATION​.‍NBTXR3 ACTIVATED BY RADIOTHERAPY INDUCES SIGNIFICANT ADAPTIVE IMMUNE PATTERN VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH SOFT TISSUE SARCOMA​.‍STRONG DATA TO SUPPORT RATIONAL FOR UPCOMING CLINICAL TRIAL IN COMBINATION WITH CHECK POINT INHIBITORS​.‍PRECLINICAL DATA ON DIFFERENT ANIMAL MODELS CONFIRM BROAD POTENTIAL OF NBTXR3 AS A PRIMER OF IMMUNE RESPONSE​.  Full Article

Nanobiotix completes new share issue for about 27.2 million euros
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES.‍ISSUES OF 1,941,789 NEW SHARES, PAR VALUE EUR 0.03​.‍ISSUE PRICE OF NEW SHARES HAS BEEN SET AT EUR 14.00 PER SHARE, REPRESENTING AN 18% DISCOUNT​.‍TRADING OF THE NEW SHARES TO START ON EURONEXT PARIS ON NOVEMBER 2, 2017​.  Full Article

Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3
Monday, 23 Oct 2017 

Oct 23 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA.‍LAST PATIENTS ARE EXPECTED TO START TREATMENT IN TWO TO THREE WEEKS​.‍EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL IN SOFT TISSUE SARCOMA IN FIRST HALF OF 2018​.  Full Article

French and Benelux stocks-Factors to watch on April 5

April 5 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.